{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"New ALK TKI treatment resulted in \\>50% reduction of ALK fusion allelle frequency","groups":[{"description":"Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)","id":"OG000","title":"ALK-positive NSCLC With Progression"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who had additional optional blood draw following initiation of new ALK TKI therapy","reportingStatus":"POSTED","timeFrame":"32 months","title":"Treatment Outcome: >50% Reduction of ALK Fusion Allelle Frequency","type":"SECONDARY","unitOfMeasure":"Participants"}